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Background:  The increased longevity of HIV patients due to modern therapy and the increased risk of coronary artery disease (CAD) in these 
patients require an integrated therapeutic approach including screening for cardiovascular diseases (CVD). The purpose of this analysis was to 
evaluate effectiveness, costs, and cost-effectiveness of different CVD screening programs for HIV patients
Methods:  We developed a microsimulation model that simulates CAD, asymptomatic systolic and diastolic dysfunction and heart failure in 
the presence of HIV. During annual cycles, patients could develop or progress in one or more of these diseases. In addition to HIV status, age, 
and gender, mortality risk depended on CVD and treatment status. Model and cost parameters were derived from patient-level data of the HIV-
HEART study in Essen, Germany (802 patients, 44.2 ±10.3 years, 83.4% male) and published literature. The model predicted quality-adjusted life 
expectancy, life-time medical costs, and cost-effectiveness. We compared (1) no screening (SOC) to (2) ECG+BNP with echo+ stress-ECG if pathologic 
ECG or BNP (Outpatient), (3) ECG+ BNP+echo+ stress-ECG (Cardio), (4) Cardio with coronary CTA if pathologic echo or stress-ECG (Cardio+).
Results:  In a male population of 40 years of age, the estimated CAD prevalence was 5.7%. Per 1000 patients, Outpatient screening correctly 
identified 4 out of 57 CAD patients at €46/person; while Cardio screening identified 41 patients at €118/person and Cardio+ 49 patients at €175/
person. The model predicted a mean discounted quality-adjusted life expectancy of 15.64 years for SOC and 15.68, 15.91, and 16.04 years for 
Outpatient, Cardio, and Cardio+, respectively. Mean discounted lifetime costs per patient were estimated at € 227,592 for SOC and € 228,465, € 
234,554, and € 236,614 for Outpatient, Cardio, and Cardio+. Cardio was extendedly dominated by Cardio+. The incremental cost-effectiveness ratio 
of Outpatient vs. SOC and Cardio+ vs. Outpatient were €21,825 and €22,636 per discounted quality-adjusted life year..
Conclusion: Preliminary results indicate that screening HIV patients for cardiovascular diseases could be clinically and economically attractive.
